Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 8/20 | 0.67 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.67 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.67 |
| ▸ | MRGPRX2 | Q96LB1 | 5/20 | 0.67 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.67 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.67 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.67 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.51 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13668804 | 1.00 | OPRM1 (0.67) | OPRM1OPRD1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL18867882 | 1.00 | OPRM1 (0.67) | OPRM1OPRD1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL14463456 | 1.00 | OPRM1 (0.67) | OPRM1OPRD1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL14154485 | 0.91 | OPRM1 (0.55) | OPRM1OPRD1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL13151540 | 0.86 | OPRM1 (0.66) | OPRM1OPRD1OPRK1MRGPRX2SLC22A1 | |
| SCHEMBL19880922 | 0.86 | OPRM1 (0.66) | OPRM1OPRD1OPRK1MRGPRX2SLC22A1 | |
| SCHEMBL18867761 | 0.86 | OPRM1 (0.66) | OPRM1OPRD1OPRK1MRGPRX2SLC22A1 | |
| SCHEMBL12283963 | 0.86 | OPRM1 (0.66) | OPRM1OPRD1OPRK1MRGPRX2SLC22A1 | |
| SCHEMBL14501896 | 0.86 | OPRM1 (0.55) | OPRM1OPRD1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL22971571 | 0.83 | OPRM1 (0.66) | OPRM1OPRD1OPRK1MRGPRX2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11560578-B2 | Neopinone isomerase and methods of using | ANTHEIA, INC. (US) | 2023-01-24 | — | — | US | disclosed |
| US-20200291438-A1 | NEOPINONE ISOMERASE AND METHODS OF USING | HERCULES CAPITAL, INC., AS AGENT | 2020-09-17 | — | — | US | disclosed |
| US-20190209551-A1 | ORAL DOSAGE FORMS FOR OXYGEN-CONTAINING ACTIVE AGENTS AND OXYL-CONTAINING POLYMER | SPRIASO LLC (US) | 2019-07-11 | — | — | US | disclosed |
| US-20150182462-A1 | Opioid-Containing Oral Pharmaceutical Compositions and Methods | UPSHER-SMITH LABORATORIES, INC. | 2015-07-02 | — | — | US | disclosed |
| WO-2009121018-A2 | OPIOID-NORNICOTINE CODRUGS FOR PAIN MANAGEMENT | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2009-10-01 | — | — | WO | disclosed |
| US-20080176885-A1 | Improved Pharmacokinetics; side effects reduction; codrugs are covalently bound by a linker that is capable of cleavage in the body; analgesics | UNIVERSITY OF KENTUCKY (US) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150182462-A1 | Opioid-Containing Oral Pharmaceutical Compositions and Methods | OPRK1, OPRM1, OPRL1 | OPRM1 2/4885OPRD1 4/4885OPRK1 1/4885 |
| US-20080176885-A1 | Improved Pharmacokinetics; side effects reduction; codrugs are covalently bound by a linker that is capable of cleavage in the body; analgesics | OPRK1, CNR1, CNR2 | OPRM1 6/4885OPRD1 7/4885OPRK1 1/4885 |
| US-20190209551-A1 | ORAL DOSAGE FORMS FOR OXYGEN-CONTAINING ACTIVE AGENTS AND OXYL-CONTAINING POLYMER | OGFR, OPRL1, OGFRL1 | OPRM1 4/4885OPRD1 6/4885OPRK1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.